Replies to post #173602 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Google is a wonderful thing if you can figure out how to use it of course.
n Search of Sleep Biomarkers of Alzheimer’s Disease: K-Complexes Do Not Discriminate between Patients with Mild Cognitive Impairment and Healthy Controls

Abstract
The K-complex (KC) is one of the hallmarks of Non-Rapid Eye Movement (NREM) sleep. Recent observations point to a drastic decrease of spontaneous KCs in Alzheimer’s disease (AD). However, no study has investigated when, in the development of AD, this phenomenon starts. The assessment of KC density in mild cognitive impairment (MCI), a clinical condition considered a possible transitional stage between normal cognitive function and probable AD, is still lacking. The aim of the present study was to compare KC density in AD/MCI patients and healthy controls (HCs), also assessing the relationship between KC density and cognitive decline. Twenty amnesic MCI patients underwent a polysomnographic recording of a nocturnal sleep. Their data were compared to those of previously recorded 20 HCs and 20 AD patients. KCs during stage 2 NREM sleep were visually identified and KC densities of the three groups were compared. AD patients showed a significant KC density decrease compared with MCI patients and HCs, while no differences were observed between MCI patients and HCs. KC density was positively correlated with Mini-Mental State Examination (MMSE) scores. Our results point to the existence of an alteration of KC density only in a full-blown phase of AD, which was not observable in the early stage of the pathology (MCI), but linked with cognitive deterioration.

Keywords: amnesic mild cognitive impairment, Alzheimer’s disease, sleep, K-complexes, EEG, cognitive decline

[LakeshoreLeo1953]

Not really arguing the existence of disturbed sleep
in all its forms in AD patients. In fact arguing
it is perhaps the "early warning sign" may indeed
have validity.

I just do not subscribe to it being a primary
identifier of any one condition which in the end
is the intent of Hampel et al pursuit of a target
for a Precision Medicine approach in this case to AD.

How many 'critics" here have attempted to debunk as mis-
diagnosed enrollees in the "original 32"?

As with interpretations of Corporate conduct, time will tell, but
a more critical application of available tools

IMHO

is most useful to future success. Not a generalized "aspirin"
designation for hopes or compounds.